Breaking News on Food and Beverage Processing and PackagingWorldUSEurope

Read more breaking news


News in brief

E.coli confirmation method approved by USDA

1 comment20-Jun-2012

SDIX E.coli system approved by USDA

A SDIX system used for confirmation of E.coli has been approved by the US Department of Agriculture (USDA) in the month the industry body started testing for newly regulated strains of the pathogen.

The RapidChek CONFIRM non-0157 STEC Immunomagnetic Separation (IMS) kit is a set of immunomagnetic beads used in the confirmation of potential samples and is listed in the USDA Microbiological Laboratory Guidebook (MLG) 5B.02 as the IMS reagents used in E.coli testing.

The USDA Food Safety Inspection Service (FSIS) began monitoring of six non-O157 shiga toxin producing E.coli (STEC), incorporating the RapidChek CONFIRM STEC test kit in their testing method earlier this month.

The system can be used to check O26, O45, O103, O111, O121 and O145 in beef products.

A spokesman from SDIX told “For example, if a sample tests positive for the stx/eae genes then for the big six O-type genes by a Polymerase Chain Reaction (PCR) method such as DuPont’s, the sample can be confirmed using the RapidChek CONFIRM IMS beads to isolate the O-type which is streaked onto selective agar plates for isolation of a single colony”.  

The system is not a screening method but the company confirmed it will be launching an“easy, rapid, lateral flow strip for non-O157 STECs” in the future.

1 comment (Comments are now closed)

E. Coli STEC infection treatment


I have read your coverage of E. coli outbreaks with great interest. For future reference, a small Montreal-based company, Thallion Pharmaceuticals has partnered with France's state-owned LFB Biotechnologies to develop the world's first treatment for Shiga toxin-producing E. coli (STEC) infection.

Shigamabs uses a proven anti-toxin approach to neutralize the two types of toxins secreted by pathogenic E. coli with the intent of preventing the incidence and/or reducing the severity of a life-threatening kidney disease called hemolytic ureic syndrome (HUS). An additional benefit of this anti-toxin approach is that it is bacterial strain independent.

The company announced positive Phase 2 (primarily safety) data a few weeks ago and plans on launching a single Phase 3 trial next year. Anyway, just thought that it would make sense to get Thallion and its Shigamabs drug on your radar.

Report abuse

Posted by Steve Kilmer
29 June 2012 | 22h082012-06-29T22:08:21Z

Key Industry Events


Access all events listing

Our events, Shows & Conferences...